Collegium Pharma (COLL) Tops Q4 EPS by 62c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Oil market losses easing as nearly 80% of disrupted supply returns, UBS says
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Collegium Reports Fourth-Quarter and Full-Year 2018 Financial Results
February 27, 2019 4:01 PM ESTXtampza® ER Prescriptions Grew 233% in 2018Net Revenue Increased to $73.4 Million for Fourth Quarter 2018 and $280.4 Million for the Full YearCash and Cash Equivalents were $146.6 million as of December 31, 2018, exceeding year-end cash guidance of $145.0 millionConference call scheduled for today at 4:30 p.m. ET
STOUGHTON, Mass., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Â Collegium Pharmaceutical, Inc. (Nasdaq:... More
